The targeted agent for the treatment of bone metastases from malignant tumors called Dishumab can act on the osteoclast signaling pathway to inhibit osteoclast activity thereby achieving anti-osteolysis after bone metastasis. Dixumab can inhibit nuclear factor-kB receptor activator ligand (RANKL), which in turn blocks the RANKL-RANK (nuclear factor-kB receptor activator)-OPG (osteoprotegerin) signaling pathway. And the enrichment of RANK can promote osteoclast activity and increase the process of osteolysis, thus causing bone destruction and pathological fracture. By inhibiting RANKL on the surface of osteoclasts to suppress their activation, maturation and osteolytic activity, Dixumab can achieve the purpose of inhibiting malignant tumor bone metastasis and bone destruction. In addition to malignant tumor bone metastasis, Dixumab can also be used for bone destruction caused by giant cell tumor of bone and multiple myeloma. Dilizumab is contraindicated in patients who are allergic to the components of the drug, hypocalcemia, and should be used with caution in pregnant or lactating women and children. There are strict indications and contraindications for the use of Dilizumab, so it is recommended that patients consult a medical professional before use, and not recommended to use on their own to avoid causing adverse reactions.